الملخص الإنجليزي
Abstract:
Quercetin, for its crucial properties, fulfills the need for a multifactor action that is useful
for the potential counterbalance of a COVID-19 infection. Given this background, the aim of the
study was to evaluate the potential effect of 3 months’ supplementation with Quercetin Phytosome®
(250 mg twice a day) as prevention against symptomatic COVID-19. In total, 120 subjects were
enrolled (males, 63; females, 57; age 49 ± 12), with 60 in the supplementation group and 60 in the
placebo group. No significant differences were detected between groups in terms of gender, smoking,
and chronic disease. Subjects underwent rapid COVID-19 diagnostic tests every 3 weeks. During
our study, 5 subjects had COVID-19, 1 out of 60 subjects in the quercetin group and 4 out of 60 in
the control group. Complete clinical remission was recorded at 7 and 15 days in the quercetin and
placebo groups, respectively. Analysis showed that, at 5 months, the COVID free survival function
(risk of infection) was 99.8% in subjects under quercetin supplementation and 96.5% in control group.
As shown by the value of EXP(B), those who had taken the supplement had a protection factor of 14%
more to not contract the COVID-19 infection than that of those who had taken a placebo. Obtained
results are encouraging, but further studies are required to add quercetin as regular prophylaxis.
